Everest Medicines (01952.HK) subsidiary enters into strategic cooperation framework agreement with Haisen to expand pharmaceutical distribution and commercialization partnerships

Gelonghui, September 9 | Everest Medicines (01952.HK) announced that on September 9, 2026, its wholly-owned subsidiary, Everest Medicines Technology Co., Ltd., entered into a strategic cooperation framework agreement with Haisen. Under this agreement, both parties agreed to establish a framework for the supply, distribution, related manufacturing, and commercialization of products in China. The Group has been developing its pharmaceutical distribution and supply chain capabilities in China and expects to obtain a Pharmaceutical Operation License in China by the end of 2026. Upon obtaining the relevant license, the Group intends to carry out pharmaceutical operation and distribution activities in accordance with applicable Good Supply Practice (GSP) requirements. In this regard, the Group plans to collaborate with Haisen (

Gelonghui FinanceSep 9 20:15

Zhitong Analysis of Stock Connect Holdings in Hong Kong | September 9

Analysis of Stock Connect Holdings in Hong Kong | September 8, 2026

Zhitong FinanceSep 9 08:30

HK Stocks Midday Review | All three major indices fell, with the tech index dropping over 1%, Zhipu AI falling nearly 10%, and Xiaomi declining more than 2%; non-ferrous metal stocks rose, with Jiangxi Copper shares gaining over 5%; the Southern Two-Times

Internet and technology stocks underperformed, with Xiaomi Group-W down 2.40% and Meituan-W up 1.94%; gold miners rose, with Zijin Gold International up 3.69% and Zijin Mining up 3.67%; oil stocks performed strongly, with Sinopec up 3.81% and Kunlun Energy up 3.63%;

Futu NewsSep 8 12:10

HK Stock Market Update | EverMed (01952) rises over 5% in early trading as NMPA approves China marketing application for new drug indication of Septinib for PSVT

Yunteng Xinyao (01952) rose more than 5% in early trading. As of press time, it was up 4.73% at HK$32.78, with a turnover of HK$151 million.Zhitong Finance APP learned that Yuntian New耀 (01952) rose

Zhitong FinanceSep 8 11:53

Day 2 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Two CAR-T therapies vie for basic medical insurance coverage as executives from multiple companies maintain on-site presence.

1. As the national reimbursement drug negotiations entered their second day, several innovative drugs and products with high clinical value were brought to the negotiating table; 2. In line with past practice, innovative drugs that are relatively more difficult to negotiate, such as anti-cancer medications and treatments for rare diseases, tend to be scheduled more intensively in the subsequent days. The lineup of participating companies suggests that this arrangement has largely been maintained.

cls.cnSep 7 07:53

The innovative drug sector continues to heat up, with AI-driven efficiency gains driving deeper penetration into clinical applications.

According to reports, the innovative drug Isatuxumab Hydrochloride Tablets (brand name: Apusivir), jointly developed by Westlake University, Westlake Laboratory, and Westlake Pharmaceutical (Hangzhou) Co., Ltd., has recently received approval for market launch.

Zhitong FinanceSep 7 06:53